Production (Stage)
Scinai Immunotherapeutics Ltd.
SCNI
$2.69
-$0.0407-1.49%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -18.34% | -11.92% | -30.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -100.28% | 26,645.83% | 26,645.83% |
| Total Operating Expenses | -- | -- | -34.32% | 30.29% | 38.67% |
| Operating Income | -- | -- | 34.32% | -30.29% | -38.67% |
| Income Before Tax | -- | -- | -951.79% | -2,238.93% | 71.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -951.79% | -2,238.93% | 71.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -951.79% | -2,238.93% | 71.01% |
| EBIT | -- | -- | 34.32% | -30.29% | -38.67% |
| EBITDA | -- | -- | 35.33% | -31.56% | -41.54% |
| EPS Basic | -- | -- | -382.77% | -1,024.62% | 89.86% |
| Normalized Basic EPS | -- | -- | 7.02% | -17.27% | 41.19% |
| EPS Diluted | -- | -- | -143.41% | -100.56% | 80.84% |
| Normalized Diluted EPS | -- | -- | 7.02% | -17.27% | 41.19% |
| Average Basic Shares Outstanding | -- | -- | 87.68% | 85.79% | 45.70% |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |